OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-15.93%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$307M
AUM Growth
+$307M
(-26%)
Cap. Flow
-$40.3M
Cap. Flow
% of AUM
-13.12%
Top 10 Holdings %
Top 10 Hldgs %
66.99%
Holding
55
New
8
Increased
13
Reduced
15
Closed
15
Top Buys
| 1 |
TG Therapeutics
TGTX
|
$15.8M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
$14.1M |
| 3 |
Biodesix
BDSX
|
$3.04M |
| 4 |
Applied Therapeutics
APLT
|
$2.22M |
| 5 |
Ocular Therapeutix
OCUL
|
$2.16M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$14.1M |
| 2 |
TELA Bio
TELA
|
$6.64M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.21M |
| 4 |
Theravance Biopharma
TBPH
|
$5.63M |
| 5 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
$5.57M |
Sector Composition
| 1 | Healthcare | 97.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Larimar Therapeutics
LRMR
$337M
| $3.35M | 1.09% |
848,500
-541,500
| -39% | -$2.14M |
|
|
NYXH
27
Nyxoah
NYXH
$220M
| $3.12M | 1.01% |
441,896
-3,104
| -0.7% | -$21.9K |
|
|
28
Biodesix
BDSX
$61.9M
| $3.04M | 0.99% |
+455,573
| New | +$3.04M |
|
29
Iovance Biotherapeutics
IOVA
$800M
| $2.78M | 0.9% |
610,000
+189,000
| +45% | +$860K |
|
|
30
Applied Therapeutics
APLT
$73.7M
| $2.22M | 0.72% |
+893,000
| New | +$2.22M |
|
|
IGMS
31
DELISTED
IGM Biosciences
IGMS
| $2.18M | 0.71% |
261,000
+197,500
| +311% | +$1.65M |
|
32
Codexis
CDXS
$218M
| $2.11M | 0.69% |
1,118,900
+443,900
| +66% | +$839K |
|
33
Verastem
VSTM
$585M
| $1.72M | 0.56% |
211,400
+109,400
| +107% | +$889K |
|
34
Precigen
PGEN
$1.42B
| $1.32M | 0.43% |
+928,500
| New | +$1.32M |
|
|
TCON
35
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $848K | 0.28% |
4,764,508
| – | – |
|
36
Xeris Biopharma Holdings
XERS
$1.27B
| $725K | 0.24% |
+390,000
| New | +$725K |
|
37
Fortress Biotech
FBIO
$87.8M
| $581K | 0.19% |
2,000,000
-1,310,000
| -40% | -$380K |
|
38
Kezar Life Sciences
KZR
$28.5M
| $506K | 0.16% |
425,000
+326,204
| +330% | +$388K |
|
39
Relmada Therapeutics
RLMD
$48.8M
| $90K | 0.03% |
+30,000
| New | +$90K |
|
|
JNCE
40
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| – | – |
-669,944
| Closed | -$918K |
|
|
THRX
41
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| – | – |
-597,500
| Closed | -$5.57M |
|
|
CBAY
42
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-566,700
| Closed | -$6.21M |
|
|
43
Theravance Biopharma
TBPH
$691M
| – | – |
-543,500
| Closed | -$5.63M |
|
44
Stereotaxis
STXS
$246M
| – | – |
-3,074,995
| Closed | -$2.95M |
|
45
Sutro Biopharma
STRO
$85.6M
| – | – |
-307,000
| Closed | -$1.43M |
|
46
ProQR Therapeutics
PRQR
$256M
| – | – |
-653,000
| Closed | -$1.06M |
|
47
Intellia Therapeutics
NTLA
$1.26B
| – | – |
-120,000
| Closed | -$4.89M |
|
48
Karyopharm Therapeutics
KPTI
$61.4M
| – | – |
-1,785,000
| Closed | -$3.2M |
|
49
Fulcrum Therapeutics
FULC
$353M
| – | – |
-143,600
| Closed | -$474K |
|
|
EDAP
50
EDAP TMS
EDAP
$103M
| – | – |
-380,000
| Closed | -$3.5M |
|